CRAPT-M: An effective prognostic predictor for hepatocellular carcinoma patients treated with locoregional-bevacizumab-immunotherapy

doi:10.3748/wjg.119588

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 25

This Article

(27)

(20)

(0)

(13)

(416)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Jul 7, 2026; 32(25): 119588
Published online Jul 7, 2026. doi: 10.3748/wjg.119588

Table 3 Baseline characteristics of hepatocellular carcinoma patients receiving locoregional-bevacizumab-immunotherapy, n (%)

Variables	Total (n = 443)	CRAPT-M-low risk (n = 58)	CRAPT-M-intermediate risk (n = 162)	CRAPT-M-high risk (n = 223)	P value
Sex					0.013
Male	396 (89.4)	47 (81.0)	141 (87.0)	208 (93.3)
Female	47 (10.6)	11 (19.0)	21 (13.0)	15 (6.7)
Age (year)					0.496
≥ 65	68 (15.3)	11 (19.0)	21 (13.0)	36 (16.1)
< 65	375 (94.7)	47 (81.0)	141 (87.0)	187 (83.9)
HBV					0.076
Yes	406 (91.6)	49 (84.5)	148 (91.4)	209 (93.7)
No	37 (8.4)	9 (15.5)	14 (8.6)	14 (6.3)
Tumor size (cm)					< 0.001
≥ 7.0	311 (70.2)	24 (41.4)	110 (67.9)	177 (79.4)
< 7.0	132 (29.8)	34 (58.6)	52 (32.1)	46 (20.6)
Tumor number					0.465
Single	137 (30.1)	19 (32.8)	55 (34.0)	63 (28.3)
Multiple	306 (69.1)	39 (67.2)	107 (66.0)	160 (71.7)
Extrahepatic metastasis					< 0.001
Yes	165 (37.2)	17 (29.3)	43 (26.5)	105 (47.1)
No	278 (62.8)	41 (70.7)	119 (73.5)	118 (52.9)
BCLC stage					< 0.001
A	34 (7.7)	10 (17.2)	22 (13.6)	2 (0.9)
B	95 (21.4)	12 (20.7)	57 (35.2)	26 (11.7)
C	314 (70.9)	36 (62.1)	83 (51.2)	195 (87.4)
Child-Pugh					< 0.001
A	384 (86.7)	58 (100.0)	155 (95.7)	171 (76.7)
B	59 (13.3)	0 (0.0)	7 (4.3)	52 (23.3)
Systemic therapies					0.901
Atezolizumab + bevacizumab	194 (43.8)	27 (46.6)	70 (43.2)	97 (43.5)
Sintilimab + bevacizumab	249 (56.2)	31 (53.4)	92 (56.8)	126 (56.5)
Transarterial therapies					0.196
HAIC	378 (85.3)	45 (77.6)	141 (87.0)	192 (86.1)
TACE	65 (14.7)	13 (22.4)	21 (13.0)	31 (13.9)
PLTs	200.7 ± 97.7	189.1 ± 91.6	213.0 ± 101.3	194.8 ± 96.1	0.124
WBC	7.6 ± 3.2	6.8 ± 3.4	7.6 ± 3.0	7.8 ± 3.3	0.08

HBV: Hepatitis B virus; BCLC: Barcelona Clinic Liver Cancer; HAIC: Hepatic arterial infusion chemotherapy; TACE: Transarterial chemoembolization; PLT: Platelet; WBC: White blood cell.

Full Size Table

Citation: Zheng ZH, Xiao R, Liu N, He BY, Yu W, Wu ZS, Chen MS, Mei J, Hu DD, Guo RP. CRAPT-M: An effective prognostic predictor for hepatocellular carcinoma patients treated with locoregional-bevacizumab-immunotherapy. World J Gastroenterol 2026; 32(25): 119588
URL: https://www.wjgnet.com/1007-9327/full/v32/i25/119588.htm
DOI: https://dx.doi.org/10.3748/wjg.119588

Zheng ZH, Xiao R, Liu N, He BY, Yu W, Wu ZS, Chen MS, Mei J, Hu DD, Guo RP. CRAPT-M: An effective prognostic predictor for hepatocellular carcinoma patients treated with locoregional-bevacizumab-immunotherapy. World J Gastroenterol 2026; 32(25): 119588 [DOI: 10.3748/wjg.119588]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.